【powershell send email with attachment】Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance
SAN FRANCISCO,powershell send email with attachment CA / ACCESSWIRE / January 2, 2019 /
Jaguar Health, Inc. (
JAGX
) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Company management will host a conference call on Monday, January 7, 2019 at 8 a.m. Eastern Time to discuss 4Q'18 performance.
Dial-In Instructions for Conference Call
When:
January 7, 2019 at 8 a.m. Eastern Time
Dial-in (US Toll Free):
800-289-0438
Dial-in (International):
323-794-2423
Conference ID number:
3695186
Live webcast on the investor relations section of Jaguar's website (
click here
)
Replay Instructions
Dial-in (US Toll Free):
844-512-2921
Dial-in (International):
412-317-6671
Conference ID number:
3695186
Replay of the webcast on the investor relations section of Jaguar's website (
click here
)
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi
®
(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit
jaguar.health
. For more information about Napo, visit
napopharma.com
.
About Mytesi
®
Mytesi
®
(crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
®
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi
®
. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at
Mytesi.com
. Crofelemer, the active ingredient in Mytesi
®
, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal
Croton lechleri
tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Story continues
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will host a conference call on January 7, 2019. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
Jaguar-JAGX
SOURCE:
Jaguar Health, Inc.
View comments
下一篇:MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages CKH, PS, WDR, and EIDX Shareholders to Contact the Firm
相关文章:
- JPMorgan Chase approved to process $15 billion in new PPP loans
- 5 Value Stocks In The Energy Sector
- Our Take On Avery Dennison's (NYSE:AVY) CEO Salary
- Big cash holdings in Europe signal unease over stock market outlook
- Green Stream Highlights Recent Video Presenting Company's Unique Solar Energy Solution
- SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Canaan Inc. and Encourages Investors with Losses to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sasol Limited of Class Action Lawsuit and Upcoming Deadline - SSL
- Coronavirus has crippled global protest movements
- Evotec to Attend Upcoming Investor Conferences
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RTI Surgical Holdings, Inc. - RTIX
相关推荐:
- Global Hospital Beds Market Report 2020: Market to Reach $5.2 Billion by 2027
- Dundee Corporation Declares Quarterly First Preference Shares, Series 2 Dividend
- U.S. telehealth companies brace for demand spike as coronavirus spread accelerates
- Will AudioEye Continue to Surge Higher?
- CME Group (CME) Reports Soft May Volumes, Shares Decline
- Terms for Nykredit's and Totalkredit's auctions - Totalkredit A/S
- Donald Trump vows 'major' steps to aid US economy amid coronavirus rise
- Dollar Slumps to Multi-year Lows; EUR/USD tracks 1.20
- Euro zone manufacturing collapses in April as virus spreads -PMI
- SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Align Technology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- INTRUSION Inc. Welcomes Experienced Chief Financial Officer, Franklin Byrd
- Insider Buying: The Viad Corp (NYSE:VVI) CEO, President & Director Just Bought US$220k Worth Of Shares
- Trintech Extends Reporting Capabilities in Its Adra Suite with the Launch of Adra Analytics
- Domino's (DPZ) Opens 17,000th Store, Expands in Australia
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spirit AeroSystems Holdings, Inc. - SPR
- Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties
- EXPLAINER-Why automakers are on a drive to sell electric cars in Europe
- Bank of Montreal: More Upside After a Significant Gain?
- X-ray Tube Market - Growth, Trends, Forecasts (2020 - 2025)
- Global Flavored Water 2019 - Key Insights and Drivers Behind the Flavored Water Market Performance